Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection. 1994

P H Frissen, and M E van der Ende, and C H ten Napel, and H M Weigel, and G S Schreij, and R H Kauffmann, and P P Koopmans, and A I Hoepelman, and J B de Boer, and G J Weverling
Department of Internal Medicine, Academic Medical Center, Amsterdam, Netherlands.

Forty-five subjects with symptomatic human immunodeficiency virus type 1 (HIV-1) infection, CD4+ lymphocyte counts of > or = 150 x 10(6)/L, and Karnofsky scores > or = 60 were enrolled in a multicenter, randomized, controlled trial that compared zidovudine monotherapy and combination therapy for 48 weeks with zidovudine and interferon-alpha (IFN-alpha). Zidovudine with IFN-alpha (n = 25) had a favorable effect on CD4+ cell counts compared with zidovudine alone (n = 20). At all time points analyzed, the mean change from baseline was higher, reaching significance at week 24 (+10% versus -21%; P = .029). At week 48 the difference was -12% versus -45% (P = .07). Anti-CD3 monoclonal antibody-induced T cell reactivity improved temporarily in both groups. Serum HIV p24 antigen levels decreased maximally during the first 12 weeks of treatment. At weeks 0 and 48, polymerase chain reaction analysis for mutations at codons 67 and 215 of the HIV-1 reverse transcriptase gene conferring zidovudine resistance was conducted in 10 subjects receiving zidovudine and in 8 subjects receiving combination therapy. At week 48, 1 of 8 and 4 of 6 samples from the groups receiving zidovudine only or combination therapy, respectively, contained wild type virus at codon 215. Grade 3 or 4 toxicity was uncommon. Drug-related malaise and anorexia were observed more frequently in patients receiving both zidovudine and IFN-alpha.

UI MeSH Term Description Entries
D008297 Male Males
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain

Related Publications

P H Frissen, and M E van der Ende, and C H ten Napel, and H M Weigel, and G S Schreij, and R H Kauffmann, and P P Koopmans, and A I Hoepelman, and J B de Boer, and G J Weverling
April 1991, The Journal of infectious diseases,
P H Frissen, and M E van der Ende, and C H ten Napel, and H M Weigel, and G S Schreij, and R H Kauffmann, and P P Koopmans, and A I Hoepelman, and J B de Boer, and G J Weverling
January 1994, International journal of clinical & laboratory research,
P H Frissen, and M E van der Ende, and C H ten Napel, and H M Weigel, and G S Schreij, and R H Kauffmann, and P P Koopmans, and A I Hoepelman, and J B de Boer, and G J Weverling
May 1992, The Journal of infectious diseases,
P H Frissen, and M E van der Ende, and C H ten Napel, and H M Weigel, and G S Schreij, and R H Kauffmann, and P P Koopmans, and A I Hoepelman, and J B de Boer, and G J Weverling
June 1999, The Journal of infectious diseases,
P H Frissen, and M E van der Ende, and C H ten Napel, and H M Weigel, and G S Schreij, and R H Kauffmann, and P P Koopmans, and A I Hoepelman, and J B de Boer, and G J Weverling
May 1995, Blood,
P H Frissen, and M E van der Ende, and C H ten Napel, and H M Weigel, and G S Schreij, and R H Kauffmann, and P P Koopmans, and A I Hoepelman, and J B de Boer, and G J Weverling
February 1994, Pediatrics,
P H Frissen, and M E van der Ende, and C H ten Napel, and H M Weigel, and G S Schreij, and R H Kauffmann, and P P Koopmans, and A I Hoepelman, and J B de Boer, and G J Weverling
May 1997, The New England journal of medicine,
P H Frissen, and M E van der Ende, and C H ten Napel, and H M Weigel, and G S Schreij, and R H Kauffmann, and P P Koopmans, and A I Hoepelman, and J B de Boer, and G J Weverling
August 1993, Annals of neurology,
P H Frissen, and M E van der Ende, and C H ten Napel, and H M Weigel, and G S Schreij, and R H Kauffmann, and P P Koopmans, and A I Hoepelman, and J B de Boer, and G J Weverling
April 1993, The New England journal of medicine,
P H Frissen, and M E van der Ende, and C H ten Napel, and H M Weigel, and G S Schreij, and R H Kauffmann, and P P Koopmans, and A I Hoepelman, and J B de Boer, and G J Weverling
October 1990, Annals of internal medicine,
Copied contents to your clipboard!